Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Hiroaki Shimokawa et al.|New England Journal of Medicine|2017Cited by 9.1k
Rosuvastatin in Older Patients with Systolic Heart FailureJohn Kjekshus, John Wikstrand, Eduard Apetrei et al.|New England Journal of Medicine|2007Cited by 1.5k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Jean MacFadyen et al.|The Lancet|2017Cited by 1.3k
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsStephen J. Nicholls, Steven E. Nissen, Rishi Puri et al.|JAMA|2016Cited by 1.1k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881